Furthermore, as mentioned in the introduction and outlined in more detail in the following section, IDH mutations have been recognized as key molecular markers of certain gliomas that distinguish them from other, more malignant forms, so that their non-invasive detection could facilitate glioma classification and therapy planning in affected patients. Here, IDH1 is linked to glioma.